The classification of kidney cancer has changed rapidly since the 1970s, when differentiating between clear cell carcinoma and granular cell carcinoma was based solely on their morphological features [1] . In 1997, the classification of kidney cancer was revised due to the identification of specific chromosomal aberrations that can differentiate distinctive types of tumours [2] . The classification of kidney cancer was updated again in 2004 to incorporate new knowledge on pathology, epidemiology, and genetics [3] , and revised in 2016 [4] . The rapid development of next generation sequencing techniques has further contributed to the molecular characterization of the subtypes of kidney cancer. This molecular characterization involves identification of mutations [5, 6] , cancer driver genes [7] , copy number variations (CNVs) [8, 9] , gene expression data [10] , and metabolic alterations [11] . The comprehensive characterization of clear cell renal cell carcinoma (ccRCC) is summarized in Table 1 .
Predicting clinical outcomes
In the next level of analyses, researchers have attempted to associate the previously identified genomic profiles of primary ccRCC with clinical outcomes. This is much more challenging as it requires detailed clinical information about the patients, including long-term follow-up data. The major subtype of kidney cancer, ccRCC, has so far received the most attention in these molecularclinical correlation studies, and the ccRCC characteristics that have significant associations with the clinical outcome are presented in Table 2 . Once the association of a genomic marker with specific clinical characteristics has been validated in large cohorts, this marker can be used to help decide on the best medical management for the patient. Morphological features Abundant clear cytoplasm due to glycogen and lipid deposition. Commonly hypervascular with the presence of coagulative tumour necrosis [12, 13] Chromosomal aberrations Most common chromosomal aberrations: 3p loss (prevalence 90%); deletion of 6q, 8p, 9p, and 14q; amplification of 5q22 and 12q [8, 9] Mutational signature The identification of cancer mutation signatures consisting of combinations of single or multiple nucleic acid base alterations. Signature 1B (prevalence 60.7%) is age-related. Signature 6 (prevalence 2.6%) is a DNA MMR deficiency [5] .
Individual genes
The most frequently mutated genes are: VHL, PBRM1, SETD2, BAP1, MTOR, KDM5C, KMT2C, and CSMD3 [6] . With the exception of CSMD3, these genes are all recognized as cancer driver genes in ccRCC based on their mutation frequency and high in silico-predicted functional impact [7] . Other ccRCC cancer driver genes are ARID1A, PTEN, and ATM mRNA  mRNAs detected as potential markers of ccRCC: CD31, EDNRB, and TSPAN7
[14]  ccA and ccB subgroups: a set of 110 genes (120 probes) that stratify ccRCCs into two groups -the ccA group, whose highly expressed genes mostly associate with angiogenesis and cellular metabolism, and the ccB group, whose highly expressed genes mostly associate with cell differentiation, epithelial to mesenchymal transition, mitosis, and the TGFβ pathway [10] .  Clear code 34: a set of 34 genes that stratify ccRCCs into two groups (a 34gene list to define ccA and ccB groups) [ 
Personalized medicine in ccRCC: choosing therapy using genomic profiles
The benefits of molecular testing can not only be applied to define the prognosis of the patients but also to select the most optimal therapy. In the last ten years, FDA-approved targeted therapy agents have brought new hope to the treatment of metastatic ccRCC. These treatments included vascular endothelial growth factor (VEGF)-targeted therapies (i.e. bevacizumab, sunitinib, axitinib, sorafenib, pazopanib, and cabozantinib) and mammalian target of rapamycin (mTOR) inhibitors (i.e. temsirolimus and everolimus). The newest immunotherapeutic agents include the drugs that target the cytotoxic T lymphocyte antigen-4 (CTLA-4) (i.e. ipilimumab) and programmed cell death protein 1 (PD-1) (i.e. nivolumab, pembrolizumab) [1] . Recent studies have sought to associate mutational profiles with the effectiveness of specific ccRCC therapies. Patients with PBRM1 mutations appear to have a good response to everolimus, as indicated by a longer median first-line progression-free survival (PFS). In contrast, patients with BAP1 mutations appear to have bad response to everolimus, as indicated by a shorter PFS [30] . The same study found that patients with KDM5C mutations had a better response to sunitib, as indicated by a longer PFS. Mutations in PBRM1 also predict a better response to anti PD-1 monotreatment (i.e. nivolumab) or its use in combination with anti-CTLA-4 (i.e. iplimumab), as these mutations were enriched in the group of patients who benefitted from this treatment [31] .
Which NGS techniques to use?
There are several options for NGS-based techniques in the clinic. For the detection of variants in specific genes, including known ccRCC cancer driver genes or even specific variants (i.e. hotspot analysis), targeted sequencing is more suitable than whole exome sequencing (WES). By limiting the number of genes in targeted sequencing, we can optimize the number of samples and the read depth of our targeted genes for each sequence run, and the costs are lower than those for WES. In addition, WES will identify many variants in genes unrelated to ccRCC, and interpretation of WES data is generally much more time-consuming than interpretation of panel data. Nonethe-less, a larger targeted gene panel or WES could be useful in cases of metastasized disease with unknown primary tumours, where combining the mutational spectrum with histomorphological analysis might be able to suggest the most likely tumour origin [32] . Whole genome sequencing (WGS) provides much more information, particularly with respect to unexplored non-coding regions and structural variations not covered by WES or targeted sequencing. Although the application of WGS is still limited to research at the moment, it may become an option in the clinic in the future [33] as sequencing costs continue to decrease and new clinically relevant genomic characteristics are discovered.
Intratumour heterogeneity and sampling strategy
Even though molecular testing by NGS has already been widely studied, its applicability is challenged by the recent discovery of intratumoural heterogeneity (ITH). This is particularly true for solid tumours, including ccRCC, that show parallel branching as the dominant pathway of evolution [34, 35] because these tend to show ITH [36] . This relatively novel phenomenon is characterized by distinct mutational or CNV profiles for tumour subregions. ITH may be present between different regions of primary ccRCCs [chapter 3 of this thesis] [37, 38] or between primary tumours and metastases of metastatic ccRCC [chapter 4 of this thesis] [39, 40] . This is also referred to as spatial heterogeneity to distinguish it from the longitudinal variations in the molecular profile of cancer cells over time, which is referred to as temporal (or longitudinal) heterogeneity [41] . All the types of ITH described above will have strong implications for large-scale application of molecular testing in the clinic. The inconsistent findings presented thus far by different studies assessing the association of mutated genes with prognosis (summarized in Supplementary Table  S1 , chapter 2 of this thesis) may indicate that ITH is a factor that influences the detection of the mutated genes across studies. ITH challenges the application of genomic marker tests, not only at the DNA level but also at the RNA level. For example, even though Gulati et al. were able to validate the significant association between ccA/ccB gene expression signatures and cancerspecific (CSS) in 350 ccRCC, ITH for these two gene expression groups was identified in some of their samples [42] . Thus, in investigating the association between genomic profiles and clinical associations, the results might be influenced by region selection bias.
Multi-region sampling
Multi-region tumour sampling is the suggested solution to overcome the challenges of spatial heterogeneity. One previous study [43] tested five genes (VHL, PBRM1, SETD2, KDM5C, and BAP1), which were also present in our panel described in chapter 2, by multi-region tissue biopsy sampling from 14 ccRCC patients. Based on their estimation, samples from at least three different tumour regions are needed to detect gene mutations with a 90% level of certainty, with the exception of VHL mutations, which, if present in any sample, were also present in all other samples from those tumours. The authors also reported that the mutation frequency detected by multiple sampling is higher than that found by single sampling in both their study and The Cancer Genome Atlas (TCGA) study. Their result is in line with a study in which multi-region sampling detected a higher frequency of driver mutations in ccRCC compared to single sampling [37] .
The other benefit of multi-region sampling is the ability to differentiate the major clone from the minor clone. In chapter 3 and chapter 4 of this thesis, we showed that multi-region sampling is very useful for determining which mutations are major clonal and which are present in a minority of the tumour cells in ccRCCs. The differentiation between major clones (as indicated by the presence of trunk mutations) and minor clones is very important for targeted therapy application [35, 44] or for tracing potential metastatic clones [45, 46] . In chapter 4 of this thesis, we showed how multi-region sampling of ccRCC helped us to find a potential metastatic clone that originated from a region of the primary tumour, as well as helping to determine how clones evolved in the venous tumour thrombus and distant metastatic sites [39] . It was previously postulated that ~76% of minor clonal mutations would have been appeared as major clonal if the sampling was performed in fewer regions [47] .
Since multi-region sampling is still bulk-tissue sampling, it has a limitation in detecting the genomic aberrations present in very small populations of cells. This is because the signatures of these small populations can be missed due to dilution within the background of tumour cells with other molecular profiles (spatial heterogeneity) and by normal cell admixture within General discussion and future perspective a tumour. The various mutant allele frequencies (MAFs) of mutations detected in each tumour region in our studies, also indicated as major and minor mutations, reflected the presence of this temporal heterogeneity (chapter 3 and 4 of this thesis). This can be circumvented, in part, by increasing sequencing depth [48] or using single-cell sequencing, as we did in chapter 5. Singlecell sequencing has supported studies aimed at describing ITH in several tumour types [49] [50] [51] [52] [53] , in tumour evolution [54] [55] [56] , and in metastatic tumour cell dissemination [57, 58] . Through lowcoverage single-cell WGS, we showed that various levels of spatial heterogeneity were present in a primary tumour and metastases of small cell lung carcinoma (SCLC). We also showed that the metastatic dissemination of this SCLC occurred through monoclonal seeding to the liver and through polyclonal seeding to the lymph nodes and adrenal gland (chapter 5 of this thesis). This spatial heterogeneity is also present in ccRCC, and the mutation profile of ccRCC obtained by single-cell sequencing can be very different from the one obtained by bulk-tissue sequencing [53] . Single-cell sequencing is not limited to tumour tissue. It can also be applied to circulating tumour cells [58] [59] [60] , which may be important for studying the process of metastasis formation. However, the application of single-cell sequencing in the clinic is currently limited by the difficulty of obtaining sufficient cells even with a large starting volume of material, the low throughput of sequencing results, the technical noise of sequencing results, and the time-consuming laboratory preparation required [61, 62] .
Longitudinal sampling to monitor therapy response and disease recurrence: the era of liquid biopsy
Following the initial surgical removal of the primary tumour, longitudinal sampling is needed to screen for disease recurrence and monitor treatment response in metastatic ccRCC patients. However, longitudinal sampling of multiple metastatic regions would generally be too large a burden for patients. The suggested alternative is longitudinal sampling using liquid biopsies. Currently, the most commonly used liquid biopsies are those from blood. Different components of tumour cells that potentially serve as biomarkers, including circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) can be found in blood plasma [63] . These tumour-derived molecules originate from the primary tumour and/or from multiple metastatic sites and provide a library of genomic data representing all the tumours present in a patient at the time of sampling. Detection of CTC and ctDNA has recently been approved by the U.S. Food and Drug Administration (USFDA) as a liquid biopsy application [64] . ctDNA is present in plasma as a subfraction of the cell-free DNA (cfDNA). It originates from DNA released from tumours due to active secretion of the tumour cells, apoptosis, tumour necrosis, or the lysis of CTCs or micrometastases [65] . ctDNA can potentially provide information on small mutations and chromosomal aberrations that are present in a patient's tumour cells. Because cell-free DNA has a half-life of between 16 minutes and 2.5 hours [66], it can be used for "real-time" genomic monitoring of treatment results and the selection of further treatment strategies. Moreover, the detected MAFs may be indicative of the tumour burden in a patient. Thus, after surgical removal of the initial tumours, the analysis of ctDNA can be used to reveal the presence of residual tumour and recurrences or occult metastasis [67, 68] .
A few studies have focussed on ctDNA analysis in ccRCC [69, 70] . By targeted sequencing of 48 the most frequently mutated genes in ccRCC, Yamamoto et al. were able to detect 38 mutations in the cfDNA of 16 out of 53 ccRCC patients [69] . Here they found complete concordance between ctDNA and tumour tissue in the detected mutations in one out of the five patients for whom they could also analyse the primary tumour. They also observed that the presence of ctDNA and a shorter fragment length of cfDNA were significantly associated with a shorter CSS. In their cohort study, Pal et al. collected ctDNA at different time points from ccRCC patients receiving first-line and later-line targeted therapy. The treatment appeared to increase the mutations and chromosomal aberrations of TP53 and other genes in mTOR pathway, such as NF1, and is likely to reflect treatment-induced selective pressure [70] . Although promising, ctDNA detection has its limitations, as the fraction of ctDNA in the total cell-free DNA present in plasma is very small, causing MAFs to be close to the detection limit of most NGS protocols.
CTCs are derived from the primary tumour through passive shedding or intravasation as an initiation of metastasis development [71, 72] . Through analysis of CTCs we can get information on the genomics, transcriptomics, cytogenetics, and proteomics of the tumour, and this may even allow for drug sensitivity testing in ex vivo cultures of CTCs [63] . The direct clinical application of CTC analysis in ccRCC was demonstrated by Kim et al. (2019) , who showed that the number of CTCs tends to associate, albeit not statistically significantly, with a worse tumour stage and CSS [73] . Ne et al. (2016) also showed that the quantity of CTCs was significantly associated with a shorter PFS and lower expression levels of HIF1A, KDR1 (VEGFR), and VEGFA [74]. However, there are still limitations to the further application of CTCs in the clinic, mainly due to the difficulty of identifying and isolating the tumour cells [61] . An additional challenge will be that current singlecell sequencing techniques may not yet be adequate to identify the full spectrum of genomic alterations in CTCs.
Concluding remarks
Several techniques of genomic sampling and molecular testing are ready to be used in the clinic. What is needed now is validation of molecular markers in various clinical settings. It should be well defined which types of genomic sampling and molecular testing are the most suitable for certain clinical outcome analyses.
The liquid biopsy technique offers a promising solution to overcome the difficulties of longitudinal sampling and the problem of sampling from non-accessible tumours. It might also help in identifying at least some of the gene variants missed by limited tumour-tissue sampling. As this technique is relatively new compared to tumour-tissue sampling, more knowledge still needs to be gained regarding the sensitivity and specificity of liquid biopsy in representing the genomic profiles of the corresponding tumours.
Molecular pathology-based diagnostics in ccRCC is now in an exciting phase of development. However, this does not imply that the conventional clinicopathological diagnoses such as tumour grade, necrosis, tumour size, and tumour stage should be neglected, as these all have an independent impact in determining a patient's clinical outcome [20, 42, 75] . The (near) future expectation is that a new consensus guideline will be established that addresses the collection of clinical information and pathologic specimens (including sampling methods), the recommended routine and ancillary pathologic testing (including the molecular testing), and patient management plus follow up strategies based on the clinicopathological and molecular information collected. In the ideal diagnostic world, there would be a well validated scoring system consisting of clinical, pathological, and molecular parameters, with a final score that stratifies ccRCC patients for optimal treatment and follow up.
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Chapter 7 Het doel van het in dit proefschrift beschreven onderzoek was om niet-erfelijke, ofwel somatische, genetische verschillen te bestuderen tussen en binnen kwaadaardige niertumoren van het zogenaamde heldercellige type (clear cell renal cell cancer, ccRCC). Deze verschillen worden ook wel genetische intra-en intertumor heterogeniteit genoemd. Omdat ccRCC vaak al gemetastaseerd is op het moment van diagnose en die gevallen moeilijk te behandelen zijn, overlijden veel patiënten aan hun tumor. De heterogeniteit van ccRCC [1, 2] is een van de uitdagingen waar men mee te maken heeft bij het proberen de diagnostiek en behandeling van dit type kanker te verbeteren. Deze heterogeniteit is al vele jaren geleden beschreven op het niveau van de met de microscoop zichtbare tumorkenmerken, de zogenaamde histomorfologische kenmerken [3, 4] . Pas meer recent is men de heterogeniteit op genetisch niveau gaan bestuderen, inclusief de relatie ervan met die histomorfologische kenmerken. Dit onderzoek nam een grote vlucht door het beschikbaar komen van een onderzoekstechniek die next-generation sequencing (NGS) wordt genoemd.
De genen die het vaakst gemuteerd zijn in ccRCC zijn inmiddels met behulp van onderzoek in grote series van die tumoren beschreven. Minder onderzoek is echter gedaan naar de prognostische betekenis van de aanwezigheid van mutaties in die genen en de verdeling van deze mutaties binnen en tussen tumorsamples, inclusief metastasen, en naar de relatie tussen die mutaties en histomorfologische tumorkenmerken. In het onderzoek beschreven in dit proefschrift gebruikten we gerichte NGS, ofwel een NGS panel van 42 genen, om de mutatieprofielen van primaire ccRCC en metastasen te achterhalen en de distributie daarvan binnen en tussen samples in kaart te brengen. We ontwierpen dit panel op basis van de bekende, meest frequent gemuteerde, genen in ccRCC en voegden daar minder frequent gemuteerde genen aan toe waarvan gesuggereerd is dat ze geassocieerd zijn met klinisch beloop en/of keuze van therapie. We breidden het genpanelonderzoek uit met 3 andere technieken: NGS van alle eiwitcoderende genen (zogenaamde whole exome sequencing), arrayCGH om variaties in de hoeveelheid van (delen van) chromosomen te bestuderen (copy number variants, CNVs) en RNA sequencing om mogelijke variaties in de activiteit van genen te achterhalen. Tenslotte, met de wens om in de toekomst ccRCC tumorheterogeniteit op nog een andere wijze te kunnen onderzoeken, hebben we de nieuwe techniek van single cell sequencing ingezet.
Hoofdstuk 1 geeft een inleiding over ccRCC en beschrijft het doel van onze verschillende onderzoeken. De daaropvolgende hoofdstukken bespreken de details van deze onderzoeken naar de genomische variantie in ccRCC en wel die in relatie tot kanker-gerelateerde overleving (hoofdstuk 2), die binnen primaire ccRCC (hoofdstuk 3) en die binnen metastasen (hoofdstuk 4). In hoofdstuk 5 rapporteren we over onze single cell sequencing experimenten in kleincellig longcarcinoom.
We gebruikten ons panel met 42 genen om het mutatieprofiel vast te stellen in 252 ccRCC tumoren verzameld binnen de prospectieve "Netherlands Cohort Study on diet and cancer (NLCS)" en analyseerden de uitkomsten hiervan in relatie tot ccRCC-specifieke overleving en klinische tumorkenmerken. In hoofdstuk 2 presenteren we data voor een groep van 110 patiënten uit dit cohort. Van de 42 genen selecteerden we de zeven genen met de hoogst gerapporteerde frequentie in ccRCC: VHL, PBRM1, SETD2, BAP1, MTOR, KDM5C, en TP53 [5, 6] . We analyseerden één sample per tumor. In deze serie werd dus wel de intertumor maar niet de intratumor heterogeniteit onderzocht. Wij vonden dat mutaties in VHL en PBRM1 geassocieerd waren met ccRCC-specifieke overleving, alhoewel die associatie niet significant bleef na multiple-testing correctie. Daarnaast zagen we een statistisch significant betere overleving bij de aanwezigheid van zowel VHL als PBRM1 mutaties. Dit effect zou te maken kunnen hebben met de rol die mutaties in beide genen hebben als 'cancer driver' in het begin van de ontwikkeling van ccRCC en in veel mindere mate tijdens progressie van de tumor, zoals SETD2 and BAP1 die wel hebben [7, 8] . In hoofdstuk 3 beschrijven we een studie waarbij zowel naar inter-als intratumor heterogeniteit werd gekeken, waarbij we ook naar de relatie tussen de genpanel bevindingen met de histomorfologische tumorkenmerken keken. Die kenmerken helpen de clinicus bij het bepalen van het behandelingsbeleid [9, 10] . In deze studie analyseerden we 31 tumor samples, met een uniforme histomorfologische tumorgraad, van zeven ccRCC patiënten. We vonden VHL mutaties in vrijwel alle samples, wat niet verrassend was gezien de hierboven genoemde rol van VHL als tumordriver [7] . Mutaties in PBRM1 werden in vier patiënten in meerdere regio's waargenomen en bij BAP1 and ROS1 was dat maar bij één patiënt het geval. We vonden voor een aantal genen mutaties die slechts in enkele regio's van de tumor van een patiënt voorkwamen. Een duidelijk verband tussen de mutaties per regio en de tumorgraad van die regio konden we niet aantonen. Wel vonden we bij de patiënt die ook met arrayCGH werd nagekeken een toename in chromosomale instabiliteit bij stijgende tumorgraad.
We breidden ons onderzoek uit met een studie naar de tumorheterogeniteit van metastasen in relatie tot de primaire ccRCC tumor. Ook wilden we deze heterogeniteit analyseren op het niveau van RNA, dat een maat is voor de activiteit (expressie) van genen. Patiënten waarbij voldoende materiaal voor onderzoek aanwezig is van zowel de primaire ccRCC als van verschillende metastasen zijn zeldzaam. In hoofdstuk 4 beschrijven we de resultaten van een patiënt met ccRCC waarbij we zowel meerdere regio's van de primaire tumor als samples van een tumortrombus in de vena cava inferior en van vier verschillende longmetastasen konden analyseren met behulp van whole exome sequencing. Behalve 18 single nucleotide varianten (SNVs) die we overal zagen, lieten alle samples een min of meer gelijke hoeveelheid, voor elk sample unieke, varianten zien. Ook op het niveau van genexpressie en copy number variants (CNVs) was sprake van heterogeniteit tussen alle samples. Net als in de studie beschreven in hoofdstuk 3 zagen we een toegenomen complexiteit van de CNV profielen bij de samples van de primaire tumor met hogere tumorgraad en bij die van de metastasen, vergeleken met die van de primaire tumor met lagere tumorgraad. Tezamen passen de bevindingen bij een scenario waarbij, tegen een achtergrond van meer geleidelijke somatische veranderingen, de ontwikkeling van ccRCC metastasen begint met een plotse snel optredende serie nieuwe mutaties, zogenaamde 'punctuated evolution' .
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